Jazz Pharmaceuticals (JAZZ) Received its Third Buy in a Row

After Oppenheimer and Evercore ISI gave Jazz Pharmaceuticals (NASDAQ: JAZZ) a Buy rating last month, the company received another Buy, this time from Wells Fargo. Analyst David Maris maintained a Buy rating on Jazz Pharmaceuticals today. The company’s shares closed last Monday at $150.38, close to its 52-week high of $153.03.

According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.2% and a 37.1% success rate. Maris covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Bausch Health Companies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $176.40 average price target, a 17.6% upside from current levels. In a report released yesterday, Barclays also maintained a Buy rating on the stock with a $200.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $153.03 and a one-year low of $113.52. Currently, Jazz Pharmaceuticals has an average volume of 523.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.